Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeff Zablocki

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Bioorganic & Medicinal Chemistry Letters|November 24, 2016
Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potencyJulie Farand, Nicholas Mai, Jayaraman Chandrasekhar, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 27, 2012
A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmiasLuiz Belardinelli, Gongxin Liu, Cathy Smith-Maxwell, et al.
Bioorganic & Medicinal Chemistry Letters|April 28, 2009
Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitorsDmitry O Koltun, Natalya I Vasilevich, Eric Q Parkhill, et al.
Journal of Medicinal Chemistry|May 15, 2020
Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis BRichard L Mackman, Michael Mish, Gregory Chin, et al.
Alcoholism, Clinical and Experimental Research|August 14, 2009
Suppression of heavy drinking and alcohol seeking by a selective ALDH-2 inhibitorMaria P Arolfo, David H Overstreet, Lina Yao, et al.
Bioorganic & Medicinal Chemistry Letters|May 29, 2019
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi<sup>®</sup>James G Taylor, Sheila Zipfel, Kyla Ramey, et al.
Bioorganic & Medicinal Chemistry|January 5, 2019
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitorDavid Sperandio, Vangelis Aktoudianakis, Kerim Babaoglu, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Bioorganic & Medicinal Chemistry Letters|November 24, 2016
Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potencyJulie Farand, Nicholas Mai, Jayaraman Chandrasekhar, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 27, 2012
A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmiasLuiz Belardinelli, Gongxin Liu, Cathy Smith-Maxwell, et al.
Bioorganic & Medicinal Chemistry Letters|April 28, 2009
Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitorsDmitry O Koltun, Natalya I Vasilevich, Eric Q Parkhill, et al.
Journal of Medicinal Chemistry|May 15, 2020
Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis BRichard L Mackman, Michael Mish, Gregory Chin, et al.
Alcoholism, Clinical and Experimental Research|August 14, 2009
Suppression of heavy drinking and alcohol seeking by a selective ALDH-2 inhibitorMaria P Arolfo, David H Overstreet, Lina Yao, et al.
Bioorganic & Medicinal Chemistry Letters|May 29, 2019
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi<sup>®</sup>James G Taylor, Sheila Zipfel, Kyla Ramey, et al.
Bioorganic & Medicinal Chemistry|January 5, 2019
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitorDavid Sperandio, Vangelis Aktoudianakis, Kerim Babaoglu, et al.
Pageof 3